Roche and Chugai have entered new dealmaking territory. This is the first time a Western company has taken over a Japanese counterpart in one go, and on a friendly basis. The deal grants Chugai enough independence for it to save face, while allowing Roche to leapfrog into the top ten in Japan. As such, the deal should in theory provide a template for others. But in Japan few CEOs are as open-minded as Chugai's leader. Equally, few Western companies can boast Roche's aptitude for arm's-length management.
by Melanie A. Senior
Roche 's acquisition of 50.1% of Chugai Pharmaceutical Co. Ltd. , Japan's tenth largest player, represents the first...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
